Age-related Macular Degeneration Market Size, Share, Growth Analysis, By Drug Type(Aflibercept, Ranibizumab, and Others), By Disease Type(Wet Age-Related Macular Degeneration (AMD) and Dry Age-Related Macular Degeneration (AMD)), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region - Industry Forecast 2024-2031

Global Age-related Macular Degeneration Market size was valued at USD 10.52 Billion in 2022 poised to grow from USD 11.24 Billion in 2023 to USD 19.18 Billion by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).

Known as age-related macular degeneration (AMD), this slow progressing condition affects the eyes’ central part—the macula—connected with the retina. It causes damage to and eventually death of cells in macula leading to gradual loss of sight among elderly people. Two main types of the disease are usually identified: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common than wet AMD, which is rarer and leads to the growth of abnormal blood vessels underneath the macula.

To minimize dry AMD propensity treatments, include vitamin supplements together with changing one’s lifestyle to be healthier. Yet for wet AMD individuals need to go for injections directly into their eye preventing formation of peculiar veins leading to designing such medications. As for its working principle this sort of treatment is recognized as anti-VEGF or aberrant endothelial growth factor therapy involved in stopping any proteins that facilitate the creation of weird blood vessels. One important aspect behind loss in sight among elderly is the global age-related macular degeneration market. The senior population's increased use of medications for age-related macular degeneration (AMD) contributes to the market's growth. Take the rise in the number of people taking these medications.